What is Zilucoplan?
Zilucoplan (brand name ZILBRYSQ, development code RA101495) is a synthetic macrocyclic peptide that selectively binds and inhibits complement component C5, the convergent step of the classical, lectin, and alternative complement pathways. Approved by the FDA in October 2023, it is the first self-administered subcutaneous peptide for anti-acetylcholine-receptor-antibody-positive generalized myasthenia gravis (AChR+ gMG).
Zilucoplan is also a notable molecule in peptide chemistry: it is one of the most clinically successful examples of a macrocyclic peptide drug — a class long pursued for its potential to combine antibody-like specificity with small-molecule manufacturability and patient convenience.
Mechanism of Action
- C5 binding — zilucoplan binds with high affinity to C5 at a site distinct from the eculizumab/ravulizumab epitope, blocking C5 cleavage by C5 convertase
- Block of C5b-9 (MAC) formation — without C5 cleavage, the membrane attack complex cannot assemble at the neuromuscular junction
- Allosteric block of C5b-C6 binding — even if any C5b is generated, zilucoplan prevents downstream MAC assembly
- Preserved upstream complement function — C3 opsonization, C3a/C5a anaphylatoxin signaling at C3 and below remain largely intact (versus full pathway inhibitors)
In AChR+ gMG, autoantibodies against the acetylcholine receptor activate complement at the postsynaptic neuromuscular junction, leading to MAC-mediated membrane damage and loss of AChR. Inhibiting C5 prevents the MAC step and protects the neuromuscular junction.
Clinical Evidence — RAISE Trial
The pivotal RAISE Phase 3 trial (NCT04115293, Lancet Neurology 2023):
- 174 adults with AChR+ gMG randomized to zilucoplan 0.3 mg/kg subcutaneous daily or placebo for 12 weeks
- Primary endpoint MG-ADL: −4.39 vs −2.30 (treatment difference −2.09, p<0.001)
- QMG score: −6.19 vs −3.25 (p<0.001)
- Improvements seen as early as week 1
- Long-term extension (RAISE-XT) shows sustained benefit through 60+ weeks
Approval History
- October 17, 2023 — FDA approval for adults with AChR+ gMG
- December 2023 — EMA approval
Why Zilucoplan Matters Beyond MG
Zilucoplan is a proof-of-concept that synthetic macrocyclic peptides can compete clinically with monoclonal antibodies in complement inhibition:
- It is administered as a once-daily 0.3 mg/kg subcutaneous self-injection — versus IV infusions every 2–8 weeks for eculizumab/ravulizumab
- Manufacturing is solid-phase peptide synthesis rather than mammalian cell culture
- Cost of goods and manufacturing scale-up profiles differ markedly from antibody therapeutics
Other complement-targeted peptides in development draw heavily on the lessons learned from zilucoplan's approval pathway.
Safety Profile
The black-box warning is for serious meningococcal infections — universal to all C5 inhibitors. Patients require N. meningitidis vaccination ≥2 weeks before initiating therapy and clinical surveillance during treatment. Other adverse events include injection-site reactions, upper respiratory infections, and headache.
Relationship to Pegcetacoplan
Zilucoplan and pegcetacoplan (Empaveli) are the two FDA-approved peptide complement inhibitors. They target different steps:
- Pegcetacoplan — pegylated cyclic peptide, C3 inhibitor (upstream)
- Zilucoplan — macrocyclic peptide, C5 inhibitor (downstream)
The two represent the leading edge of peptide-based complement therapeutics.